Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
Phase 2
Recruiting
- Conditions
- Myelodysplastic SyndromeRefractory Acute Myeloid LeukemiaHigh Risk Myelodysplastic SyndromeAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaRecurrent Acute Myeloid Leukemia
- Interventions
- Drug: Gemtuzumab OzogamicinDrug: Liposome-encapsulated Daunorubicin-CytarabineOther: Quality-of-Life Assessment
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT03672539
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Quitting Schedule Mobile Smartphone Application in Helping Participants to Quit Smoking
Not Applicable
Withdrawn
- Conditions
- Malignant NeoplasmCurrent Every Day SmokerCurrent SmokerCigarette Smoker
- Interventions
- Other: Internet Mobile TechnologyOther: InterviewOther: Questionnaire AdministrationBehavioral: Smoking Cessation Intervention
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT03668769
Tailored Smoking Cessation Intervention in Promoting Sexual and Gender Minority Smokers to Quit Smoking
Not Applicable
Completed
- Conditions
- Cigarette SmokerCurrent Every Day Smoker
- Interventions
- Other: Informational InterventionBehavioral: Telephone-Based Intervention
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2020-04-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT03669120
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Quizartinib, Decitabine, and Venetoclax in Treating Participants with Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Phase 1
Recruiting
- Conditions
- Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaRecurrent Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 73
- Registration Number
- NCT03661307
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Survey of Post-Acute Inpatient Rehabilitation Safety Concerns in Participants With Cancer
Completed
- Conditions
- Malignant Neoplasm
- Interventions
- Other: Survey Administration
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 261
- Registration Number
- NCT03656224
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Anamorelin Hydrochloride in Reducing Anorexia in Patients with Advanced Non-small Cell Lung Cancer
Phase 2
Active, not recruiting
- Conditions
- AnorexiaLung Non-Small Cell CarcinomaStage III Lung Cancer AJCC V8Stage IIIA Lung Cancer AJCC V8Stage IIIB Lung Cancer AJCC V8Stage IIIC Lung Cancer AJCC V8Stage IV Lung Cancer AJCC V8Stage IVA Lung Cancer AJCC V8Stage IVB Lung Cancer AJCC V8
- Interventions
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT03637816
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia
Phase 1
Terminated
- Conditions
- Refractory Acute Myeloid LeukemiaAcute Myeloid LeukemiaRecurrent Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT03634228
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer
Phase 1
Active, not recruiting
- Conditions
- Stage II Cervical Cancer AJCC v8Stage II Vaginal Cancer AJCC v8Stage IIA1 Cervical Cancer AJCC v8Stage IIB Vaginal Cancer AJCC v8Stage III Cervical Cancer AJCC v8Stage IIIA Cervical Cancer AJCC v8Human Papillomavirus-Related CarcinomaStage IIA Cervical Cancer AJCC v8Stage IIA Vaginal Cancer AJCC v8Stage IIB Cervical Cancer AJCC v8
- Interventions
- Radiation: Internal Radiation TherapyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT03634267
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study
Phase 2
Recruiting
- Conditions
- Stage I Lung Cancer AJCC v8Stage IA3 Lung Cancer AJCC v8Stage IIA Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Lung Non-Small Cell CarcinomaStage IA1 Lung Cancer AJCC v8Stage IA2 Lung Cancer AJCC v8Stage IB Lung Cancer AJCC v8Stage II Lung Cancer AJCC v8
- Interventions
- Biological: PembrolizumabOther: Quality-of-Life AssessmentProcedure: Computed TomographyProcedure: Biospecimen Collection
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT03634241
- Locations
- 🇺🇸
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Phase 1
Recruiting
- Conditions
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveHigh Risk Myelodysplastic SyndromeMyeloproliferative NeoplasmRefractory Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeVery High Risk Myelodysplastic SyndromeChronic Myelogenous Leukemia, BCR-ABL1 PositiveMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 58
- Registration Number
- NCT03630991
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath